These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29263422)

  • 1. Concomitant activation of ETS-like transcription factor-1 and Death Receptor-5 via extracellular signal-regulated kinase in withaferin A-mediated inhibition of hepatocarcinogenesis in mice.
    Kuppusamy P; Nagalingam A; Muniraj N; Saxena NK; Sharma D
    Sci Rep; 2017 Dec; 7(1):17943. PubMed ID: 29263422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic elucidation of the antitumor properties of withaferin a in breast cancer.
    Nagalingam A; Kuppusamy P; Singh SV; Sharma D; Saxena NK
    Cancer Res; 2014 May; 74(9):2617-29. PubMed ID: 24732433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERK/ribosomal S6 kinase (RSK) signaling positively regulates death receptor 5 expression through co-activation of CHOP and Elk1.
    Oh YT; Liu X; Yue P; Kang S; Chen J; Taunton J; Khuri FR; Sun SY
    J Biol Chem; 2010 Dec; 285(53):41310-9. PubMed ID: 21044953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of ERK1/2-mediated ELK1/CHOP/DR5 pathway in 6-(methylsulfinyl)hexyl isothiocyanate-induced apoptosis of colorectal cancer cells.
    Yano S; Wu S; Sakao K; Hou DX
    Biosci Biotechnol Biochem; 2019 May; 83(5):960-969. PubMed ID: 30730256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma.
    Ma J; Zeng S; Zhang Y; Deng G; Qu Y; Guo C; Yin L; Han Y; Cai C; Li Y; Wang G; Bonkovsky HL; Shen H
    Cancer Lett; 2017 Dec; 411():117-129. PubMed ID: 28987388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compound Astragalus and Salvia miltiorrhiza extract inhibits hepatocellular carcinoma progression via miR-145/miR-21 mediated Smad3 phosphorylation.
    Wu C; Chen W; Fang M; Boye A; Tao X; Xu Y; Hou S; Yang Y
    J Ethnopharmacol; 2019 Mar; 231():98-112. PubMed ID: 30412748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.
    Oh YT; Deng J; Yue P; Sun SY
    Sci Rep; 2016 May; 6():26803. PubMed ID: 27222248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pravastatin attenuates the action of the ETS domain-containing protein ELK1 to prevent atherosclerosis in apolipoprotein E-knockout mice via modulation of extracellular signal-regulated kinase 1/2 signal pathway.
    Yan W; Li D; Zhou X
    Clin Exp Pharmacol Physiol; 2017 Mar; 44(3):344-352. PubMed ID: 27998006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of TNF-related apoptosis-inducing Ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing Ligand in human hepatocellular carcinoma.
    Chen XP; He SQ; Wang HP; Zhao YZ; Zhang WG
    World J Gastroenterol; 2003 Nov; 9(11):2433-40. PubMed ID: 14606071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
    Blivet-Van Eggelpoël MJ; Chettouh H; Fartoux L; Aoudjehane L; Barbu V; Rey C; Priam S; Housset C; Rosmorduc O; Desbois-Mouthon C
    J Hepatol; 2012 Jul; 57(1):108-15. PubMed ID: 22414764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on effect and mechanism of Honokiol enhancing tumor necrosis factor-related apoptosis inducing ligand against hepatocellular carcinoma HepG2 cells via activating JNK signaling pathway].
    Xiao G; Yang R; Dang L; Dong CL
    Zhonghua Gan Zang Bing Za Zhi; 2018 Jun; 26(6):441-445. PubMed ID: 30317758
    [No Abstract]   [Full Text] [Related]  

  • 13. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis.
    Tyagi A; Agarwal R; Agarwal C
    Oncogene; 2003 Mar; 22(9):1302-16. PubMed ID: 12618755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prion formation correlates with activation of translation-regulating protein 4E-BP and neuronal transcription factor Elk1.
    Allard EK; Grujic M; Fisone G; Kristensson K
    Neurobiol Dis; 2013 Oct; 58():116-22. PubMed ID: 23742760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.
    Oh YT; Deng J; Yue P; Owonikoko TK; Khuri FR; Sun SY
    Oncogene; 2016 Jan; 35(4):459-67. PubMed ID: 25867065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of the response of B16F1 melanoma to fractionated radiotherapy and prolongation of survival by withaferin A and/or hyperthermia.
    Kalthur G; Pathirissery UD
    Integr Cancer Ther; 2010 Dec; 9(4):370-7. PubMed ID: 20713375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
    Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
    J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model.
    Rajasekaran D; Siddiq A; Willoughby JL; Biagi JM; Christadore LM; Yunes SA; Gredler R; Jariwala N; Robertson CL; Akiel MA; Shen XN; Subler MA; Windle JJ; Schaus SE; Fisher PB; Hansen U; Sarkar D
    Oncotarget; 2015 Sep; 6(28):26266-77. PubMed ID: 26313006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.